- Home
- GNLX vs FRES Comparison
GNLX vs FRES Comparison
Compare GNLX & FRES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- FRES
- Stock Information
- Founded
- GNLX 2001
- FRES 2010
- Country
- GNLX United States
- FRES United States
- Employees
- GNLX N/A
- FRES N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- FRES Medical Specialities
- Sector
- GNLX Health Care
- FRES Health Care
- Exchange
- GNLX Nasdaq
- FRES Nasdaq
- Market Cap
- GNLX 103.6M
- FRES N/A
- IPO Year
- GNLX 2023
- FRES 2020
- Fundamental
- Price
- GNLX $2.27
- FRES $1.12
- Analyst Decision
- GNLX Strong Buy
- FRES
- Analyst Count
- GNLX 4
- FRES 0
- Target Price
- GNLX $18.25
- FRES N/A
- AVG Volume (30 Days)
- GNLX 142.7K
- FRES 13.5K
- Earning Date
- GNLX 11-14-2024
- FRES 12-31-2024
- Dividend Yield
- GNLX N/A
- FRES N/A
- EPS Growth
- GNLX N/A
- FRES N/A
- EPS
- GNLX N/A
- FRES N/A
- Revenue
- GNLX $8,000.00
- FRES $2,341,326.00
- Revenue This Year
- GNLX N/A
- FRES N/A
- Revenue Next Year
- GNLX N/A
- FRES N/A
- P/E Ratio
- GNLX N/A
- FRES N/A
- Revenue Growth
- GNLX N/A
- FRES 94.50
- 52 Week Low
- GNLX $1.60
- FRES $0.85
- 52 Week High
- GNLX $16.60
- FRES $9.03
- Technical
- Relative Strength Index (RSI)
- GNLX 38.68
- FRES 42.61
- Support Level
- GNLX $2.13
- FRES $1.00
- Resistance Level
- GNLX $2.80
- FRES $1.40
- Average True Range (ATR)
- GNLX 0.20
- FRES 0.22
- MACD
- GNLX -0.04
- FRES -0.01
- Stochastic Oscillator
- GNLX 14.21
- FRES 23.55
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.